A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
Bayer
Aktis Oncology, Inc.
Novartis
Kumquat Biosciences Inc.
National Institutes of Health Clinical Center (CC)
Incyte Corporation
Seagen Inc.
Boehringer Ingelheim
Seagen Inc.
Seagen Inc.
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Compass Therapeutics
Pliant Therapeutics, Inc.
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Compass Therapeutics
BioNTech SE
Aurigene Discovery Technologies Limited
Aurigene Discovery Technologies Limited
Bristol-Myers Squibb
Eli Lilly and Company
Pheon Therapeutics
AstraZeneca
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Kivu Bioscience Inc.
Instil Bio
AstraZeneca
BeOne Medicines
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Bristol-Myers Squibb
Exelixis
BeOne Medicines
Astellas Pharma Inc
Institut Claudius Regaud
National Institutes of Health Clinical Center (CC)
BioNTech SE
Kura Oncology, Inc.
Zymeworks BC Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
AstraZeneca
AbbVie